Matthew Guo

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

Hepatology, Medicine, Randomised Phase 3 +11

Chemoradiotherapy of Locally Advanced Esophageal Cancer

Jay S. Cooper, Matthew Guo, Arnold Herskovic et al. · JAMA · 1999 · 1.9K citations

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet · 2016 · 753 citations · Full text

Oncology, Metronomic Therapy, Pharmacology +6

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Vicky Makker, Drew Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2019 · 470 citations · Full text

Advanced Endometrial Cancer, Interim Analysis, Medicine +6

Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism

Munro Peacock, John P. Bilezikian, Preston Klassen et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 463 citations · Full text